Harvard Bioscience Inc (HBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, HBIO trades at $5.40 with a market cap of $22.55M and a P/E ratio of -5.89. HBIO moved +0.00% today. Year to date, HBIO is -20.98%; over the trailing twelve months it is +60.52%. Its 52-week range spans $2.81 to $28.20. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces HBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes HBIO SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $5.40 |
| Market Cap | $22.55M |
| P/E Ratio | -5.89 |
| EPS | $-0.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.20 |
| 52-Week Low | $2.81 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $85.53M |
| Net Income | $-9.78M |
| Gross Margin | 58.42% |
1 analysts cover HBIO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.